



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	L-Glutamine (Endari)	Page:	1 of 2
Effective Date:	8/1/2024	Last Review Date:	7/30/2024
Applies to:	<input checked="" type="checkbox"/> Illinois <input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Florida <input checked="" type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Florida Kids

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for the generic L-Glutamine under the patient's prescription drug benefit.

Description:

L-Glutamine is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

L-Glutamine

Policy/Guideline:

Prescriber Specialties

L-Glutamine must be prescribed by or in consultation with a hematologist or specialist in sickle cell disease.

Criteria for Initial Approval:

Sickle cell disease, to reduce the acute complications

Authorization of 12 months may be granted for use in reducing the acute complications of sickle cell disease in members 5 years of age or older when EITHER of the following criteria is met:

- A. Member has sickle hemoglobin C (HbSC) or sickle β^+ -thalassemia (HbS β^+) genotype
- B. Member has homozygous hemoglobin S (HbSS) or sickle β^0 -thalassemia (HbS β^0) genotype AND meets ANY of the following:
 1. Has experienced, at any time in the past, an inadequate response or intolerance to a trial of hydroxyurea.
 2. Has a contraindication to hydroxyurea.
 3. Will be using L-Glutamine with concurrent hydroxyurea therapy.

Criteria for Continuation of Therapy:

Sickle cell disease, to reduce the acute complications

Authorization of 12 months may be granted for continued treatment when the member experienced a reduction in acute complications of sickle cell disease (e.g., reduction in the number of painful vaso-occlusive episodes, acute chest syndrome episodes, fever, occurrences of priapism, splenic sequestration) since initiating therapy with L-Glutamine.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: L-Glutamine (Endari) Page: 2 of 2

Effective Date: 8/1/2024 Last Review Date: 7/30/2024

Applies to: Illinois Florida New Jersey
 Maryland Pennsylvania Kids Florida Kids

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Limits: 180 packets per 30 days

References:

1. Endari [package insert]. Torrance, CA: Emmaus Medical, Inc; October 2020.
2. Niihara Y, Miller ST, et al. A phase 3 trial of l-glutamine in sickle cell disease. *N Engl J Med.* 2018;379(3):226-235.